At 17:00 (Sweden: 11:00 Am) on June 24, 2020 in Beijing, exchange meeting of China and Sweden Joint Scientific Research Group on COVID-19 -- Clinical Group/Public Health and Policy Group was held by video. The meeting was co-chaired by Qu Jieming, Professor of Ruijin hospital, Shanghai Jiao Tong University School of Medicine, and Anders Sönnerborg, Professor of Depts Medicine and Laboratory Medicine, Senior Physician Karolinska University Hospital.
Yihai Cao, professor of Dept Microbiology, Tumor and Cell Biology of Karolinska Institutet, introduced the therapeutic regimen on COVID-19; Erik Eliasson, professor of Dept Laboratory Medicine, Senior Physician Karolinska University Hospital introduced his research theme--variability in drug response and research tools; Professor Paolo Parini, Dept Medicine, Senior Physician Karolinska University Hospital introduced the multinational network medicine COVID-19 study;
Wang Fu-Sheng, CAS Member, Professor of Treatment and Research Center for Infectious Diseases in Fifth Medical Center of Chinese PLA General Hospital, introduced the pathological findings of virus associated with acute respiratory distress syndrome. Professor Zhang Wenhong, Department of Infectious Diseases, Huashan Hospital, Fudan University, said the world's first healthy volunteer has been dosed in a phase-1 study of a SARS-CoV-2 neutralizing antibody. It was also the first antibody of this kind to enter the clinical stage in China. There may be a rebound in autumn and winter with new cases. He hopes to work with Sweden to evaluate the efficacy of the new drug in the future.
Scientists at the meeting shared their researches and experiences in the fight against COVID-19. Both sides agreed on the importance of this meeting as a platform to learn about research areas of interest to each other, get to know different research teams, and hope to strengthen cooperation in the future to fight COVID-19.